Latest news about Bacil Pharma
Bacil Pharma
41.85
+0.10(+0.24%)
Company Performance:
View Company Insights1D+0.24%
1M-19.80%
6M+21.94%
1Y+16.90%
5Y+498.71%
More news about Bacil Pharma
22May 26
Bacil Pharma FY26 net loss widens to ₹61.88 lakh
Bacil Pharma announced its audited financial results for FY26, reporting a net loss of ₹61.88 lakh compared to ₹6.17 lakh in the previous year. Revenue from operations fell to nil, with total revenue derived solely from other income of ₹123.52 lakh. Total expenses reduced to ₹24.50 lakh. For Q4 FY26, the net loss was ₹164.14 lakh, impacted by fair valuation losses on financial assets. Total assets rose to ₹2739.26 lakh, while cash and cash equivalents decreased to ₹56.85 lakh.
11May 26
Bacil Pharma Schedules Board Meeting on May 22, 2026 to Approve Q4 FY26 Audited Financial Results
Bacil Pharma has informed BSE Limited of a Board of Directors meeting to be held on May 22, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The intimation was filed on May 11, 2026, by Ms. Chaitali Kalpataru Shah, Director and CFO, in compliance with Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting agenda also includes any other business with the permission of the Chairperson.
14Apr 26
Bacil Pharma Limited Submits Quarterly Compliance Certificate for Q4FY26
Bacil Pharma Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4FY26, confirming compliance with dematerialization procedures. The certificate, issued by Bigshare Services Pvt. Ltd., validates proper securities listing, certificate cancellation, and record maintenance within regulatory timelines. The submission demonstrates the pharmaceutical company's adherence to SEBI depositories regulations.
24Feb 26
Bacil Pharma Responds to BSE on Stock Price Movement Clarification
Bacil Pharma Limited responded to BSE's February 24, 2026 inquiry about stock price movements, confirming no unpublished price sensitive information exists. The company attributed recent fluctuations to market-driven factors and reaffirmed compliance with SEBI regulations and commitment to transparency.
23Feb 26
Norbexi Industries Limited Completely Divests 14.46% Stake in Bacil Pharma Limited
Norbexi Industries Limited has completely divested its 14.46% stake in Bacil Pharma Limited, selling 2,075,000 shares through an off-market transaction on February 19, 2026. The disclosure filed under SEBI regulations shows the company's complete exit from its investment in the pharmaceutical firm, reducing its holding from 14.46% to zero. The transaction was executed off-market and represents a significant change in Norbexi Industries' investment portfolio.
13Feb 26
Bacil Pharma Reports Strong Q3FY26 Turnaround with ₹3.92 Lakh Profit
Bacil Pharma Limited reported strong Q3FY26 results with a profit of ₹3.92 lakhs versus a loss of ₹6.20 lakhs in Q3FY25. Nine-month profit surged 85.98% to ₹72.17 lakhs from ₹38.81 lakhs YoY. The company demonstrated effective expense management while maintaining revenue growth, with total expenses declining 61.08% in Q3FY26.
30Dec 25
Khem-Sum Apparels Overseas Ltd. Disposes Complete Stake in Bacil Pharma Limited
Khem-Sum Apparels Overseas Ltd. has completely disposed of its 200-share holding in Bacil Pharma Limited through an off-market sale on December 29, 2025. The promoter group entity's stake has been reduced from 0.001% to zero, representing a complete exit from the pharmaceutical company. The transaction was disclosed under SEBI regulations on December 30, 2025.
29Dec 25
Bacil Pharma Promoter Suman P. Shah Sells Shares
Bacil Pharma Limited received a substantial disposal disclosure from promoter Suman P. Shah. The promoter sold 500 equity shares through market transactions on December 24, 2025, reducing their shareholding from 0.00% to zero. The company's total equity base of 14,353,000 shares remains unchanged.
19Dec 25
Bacil Pharma Limited Appoints New Company Secretary Following Recent Resignation
Bacil Pharma Limited announced the proposed appointment of Mr. Dikshant Singh Panwar as Company Secretary, replacing Bhavana Phoolchand Tak who resigned effective December 1, 2025. The new appointee holds membership number ACS42741 and has extensive compliance experience. The appointment requires board confirmation and follows SEBI regulatory requirements.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Zydus Life Science
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,874.40
(+0.34%)
6,753.50
(+0.10%)
4,504.40
(-0.21%)
1,437.90
(+0.33%)
1,328.40
(+2.08%)
1,099.30
(-1.16%)
2,367.60
(+0.42%)
2,483.00
(-1.80%)
1,530.60
(-0.23%)
1,454.20
(-1.81%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
